MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.radonc.2022.09.006

Медицинская библиотека · Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology · 2022

OPTimizing Irradiation through Molecular Assessment of Lymph node (OPTIMAL): a randomized clinical trial.

Algara Manuel, Rodríguez Elvira, Martínez-Arcelus Francisco José, Salinas Juan, Sanz Xavier, Beato Inmaculada, Manso Aurea, Soler Ana, Rodríguez José Reyes, Frías Andere, Calín Ana, Juan Germán, Meireles Pedro, Flaquer Amanda, OPTIMAL investigators

Рандомизированное исследованиеСтатьяПоддержка исследования: вне правительства СШАEquivalence TrialПеревод пока не подготовлен

Аннотация

BACKGROUND AND PURPOSE: In breast cancer (BC) patients, the involvement of four or more lymph nodes (LN) is an indication of regional irradiation. The optimal treatment strategy remains unclear when fewer nodes are involved and lymphadenectomy is not performed. We designed a clinical trial to show the non-inferiority of Incidental (INC) compared to intentional (INT) irradiation of axillary nodes in patients with early-stage BC and low burden LN involvement.

MATERIALS AND

METHODS

BC patients, cN0 (n = 487) undergoing breast conservation surgery and sentinel node biopsy, with total tumor load assessed by OSNA (One-Step Nucleic Acid Amplification) of 250-15,000 copies mRNA CK19/µL in sentinel LN were randomized to receive INC or INT nodal irradiation. The primary endpoint was 5-year disease-free survival (DFS). Secondary endpoints were locoregional recurrence (LRR), distant recurrence (DR), and acute and chronic toxicity (CT).

RESULTS

Five-years DFS were 93.7% (INC) and 93.8% (INT) (difference 0.1% [one-sided 95% CI < 5.7%]; non-inferiority p = 0.075). Cumulative Incidences of LRR were 3.5% (INC) and 3.4% (INT) (difference of 0.1% [<4.8%]; p = 0.021), and 5% (INC) and 3.5% (INT) (difference 1.4% [<6.0%]; non-inferiority p = 0.101) for DR. CT was more Incident with INT (26.9%) than with INC (19.2%), though the difference was not statistically significant (HR 1.39 [95% CI: 0.92, 2.10]; p = 0.11).

CONCLUSION

Intentional does not outperform incidental irradiation by more than 5.7% in terms of 5-year DFS, 4.8% for LRR, and 6% for DR.

REGISTRATION NUMBER: ClinicalTrials.gov Identifier: NCT02335957.

Для цитирования: Algara Manuel, Rodríguez Elvira, Martínez-Arcelus Francisco José, Salinas Juan, Sanz Xavier, Beato Inmaculada, Manso Aurea, Soler Ana, Rodríguez José Reyes, Frías Andere, Calín Ana, Juan Germán, Meireles Pedro, Flaquer Amanda, OPTIMAL investigators. OPTimizing Irradiation through Molecular Assessment of Lymph node (OPTIMAL): a randomized clinical trial.. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2022. DOI: 10.1016/j.radonc.2022.09.006.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.